본문으로 건너뛰기
← 뒤로

Advances in MUC1 resistance to chemotherapy in pancreatic cancer.

1/5 보강
Journal of chemotherapy (Florence, Italy) 📖 저널 OA 2.1% 2023: 0/1 OA 2024: 0/1 OA 2025: 1/18 OA 2026: 0/27 OA 2023~2026 2024 Vol.36(6) p. 449-456
Retraction 확인
출처

Yao Y, Fan D

📝 환자 설명용 한 줄

The incidence of pancreatic cancer (PC), a highly fatal malignancy, is increasing every year.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Yao Y, Fan D (2024). Advances in MUC1 resistance to chemotherapy in pancreatic cancer.. Journal of chemotherapy (Florence, Italy), 36(6), 449-456. https://doi.org/10.1080/1120009X.2023.2282839
MLA Yao Y, et al.. "Advances in MUC1 resistance to chemotherapy in pancreatic cancer.." Journal of chemotherapy (Florence, Italy), vol. 36, no. 6, 2024, pp. 449-456.
PMID 38006297 ↗

Abstract

The incidence of pancreatic cancer (PC), a highly fatal malignancy, is increasing every year. Chemotherapy is an important treatment for it in addition to surgery, yet most patients become resistant to chemotherapeutic agents within a few weeks of treatment initiation.​ MUC1 is a highly glycosylated transmembrane protein, and studies have shown that aberrantly glycosylated overexpression of MUC1 is involved in regulating the biology of chemoresistance in cancer cells. This article summarizes the mechanism of MUC1 in PC chemoresistance and reviews MUC1-based targeted therapies.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반